Literature DB >> 20849845

Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620.

I K Tentes1, W M Schmidt, G Krupitza, G G Steger, W Mikulits, A Kortsaris, R M Mader.   

Abstract

Treatment resistance to antineoplastic drugs represents a major clinical problem. Here, we investigated the long-term stability of acquired resistance to 5-fluorouracil (FU) in an in vitro colon cancer model, using four sub-clones characterised by increasing FU-resistance derived from the cell line SW620. The resistance phenotype was preserved after FU withdrawal for 15weeks (~100 cell divisions) independent of the established level of drug resistance and of epigenetic silencing. Remarkably, resistant clones tolerated serum deprivation, adopted a CD133(+) CD44(-) phenotype, and further exhibited loss of membrane-bound E-cadherin together with predominant nuclear β-catenin localisation. Thus, we provide evidence for a long-term memory of acquired drug resistance, driven by multiple cellular strategies (epithelial-mesenchymal transition and selective propagation of CD133(+) cells). These resistance phenomena, in turn, accentuate the malignant phenotype.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849845     DOI: 10.1016/j.yexcr.2010.09.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.

Authors:  Kerry M Bauer; Paul A Lambert; Amanda B Hummon
Journal:  Proteomics       Date:  2012-06       Impact factor: 3.984

2.  Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.

Authors:  Chih-Hung Lin; Wan-Tzu Chen; Chia-Hsing Liu; Hung-Pei Tsai; Chun-Chieh Wu; Chee-Yin Chai
Journal:  Virchows Arch       Date:  2012-03-28       Impact factor: 4.064

Review 3.  CD133: a cancer stem cells marker, is used in colorectal cancers.

Authors:  Fei Ren; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

4.  SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.

Authors:  Victoria J Findlay; Cindy Wang; Lourdes M Nogueira; Katie Hurst; Daniel Quirk; Stephen P Ethier; Kevin F Staveley O'Carroll; Dennis K Watson; E Ramsay Camp
Journal:  Mol Cancer Ther       Date:  2014-09-23       Impact factor: 6.261

5.  Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.

Authors:  Kaja Lund; Jennifer L Dembinski; Nina Solberg; Alfonso Urbanucci; Ian G Mills; Stefan Krauss
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  Pien Tze Huang induces apoptosis and inhibits proliferation of 5-fluorouracil-resistant colorectal carcinoma cells via increasing miR-22 expression.

Authors:  Zhaorong Chen; Aling Shen; Liya Liu; Youqin Chen; Jianfeng Chu; Qiaoyan Cai; Fei Qi; Thomas Joseph Sferra; Jun Peng
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

7.  Noscapine Induces Apoptosis in Human Colon Cancer Cells by Regulating Mitochondrial Damage and Warburg Effect via PTEN/PI3K/mTOR Signaling Pathway.

Authors:  Xia Tian; Meng Liu; Xiaodong Huang; Qingxi Zhu; Weijie Liu; Wei Chen; Yanli Zou; Yishan Cai; Shasha Huang; Aifang Chen; Ting Zhan; Min Huang; Xiaoli Chen; Zheng Han; Jie Tan
Journal:  Onco Targets Ther       Date:  2020-06-11       Impact factor: 4.147

8.  Inhibition of p38 MAPK increases the sensitivity of 5-fluorouracil-resistant SW480 human colon cancer cells to noscapine.

Authors:  Zheng Han; Liu Meng; Xiaodong Huang; Jie Tan; Weijie Liu; Wei Chen; Yanli Zou; Yishan Cai; Shasha Huang; Aifang Chen; Ting Zhan; Min Huang; Xiaoli Chen; Xia Tian; Qingxi Zhu
Journal:  Oncol Lett       Date:  2021-12-17       Impact factor: 2.967

9.  CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.

Authors:  Khalilullah Mia-Jan; So Young Jung; Ik-Yong Kim; Sung Soo Oh; EunHee Choi; Sei Jin Chang; Tae Young Kang; Mee-Yon Cho
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

10.  Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran.

Authors:  Anahita Nosrati; Farshad Naghshvar; Iradj Maleki; Fatemeh Salehi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.